There are about 11304 clinical studies being (or have been) conducted in Denmark. The country of the clinical trial is determined by the location of where the clinical research is being studied. Most studies are often held in multiple locations & countries.
Treatment with nitrate has shown to lower blood pressure in both healthy subjects and hypertensive patients.Beside this nitrate have also shown to decrease arterial stiffness and improve endothelial function.But the effect of nitrate on renal blood flow, kidney function, water and salt balance and vasoactive hormones is still unclear. Therefore, the purpose of this study is to investigate the effect of orally administered nitrate on these parameters. This will be done in a double-blinded, placebo-controlled, crossover study. 20 healthy subjects will be treated, in a randomized order, with both potassium nitrate and placebo separated by at least 4 weeks wash-out.
The trial investigates and describes the prevalence of COPD in patients who are in the social nurses' target group and investigates the effect of opportunistic screening for COPD in these vulnerable patients. The study population is patients who have been referred to a social nurse at hospitals in the Capital Region, Central Denmark Region and Region Zealand of Denmark during the inclusion period, and monitor them for up to 5 years in order to investigate variables that are significant in terms of the patients' treatment, hospitalisations, and mortality in relation to COPD. Our hypothesis is that there will be a higher incidence of COPD among those patients with whom the social nurses have contact than in the general population.
The project looks at causes of appetite loss in patients with COPD. It is know that active systemic inflammation can lead to appetite loss and COPD is classified as a disease lead by inflammation. But it has never been investigated if the patient with COPD has other causes of appetite loss such as physical, psychological or social barriers for not reaching a sufficient dietary intake. The study uses a homemade questionnaire, the CAT-scale and the CNAQ-score to evaluate the extent of appetite loss and certain demographic characteristics of the participants. There will be made correlation analysis for CNAQ-score and continuous variables and there will be tested for significant differences between the group who scores as low appetite and the group that scores with a normal appetite via CNAQ. The second part of the study invites patients to participate in a semi-structured interview, that focuses on the patient's experience with appetite loss, meals and food. The interviews will be transcribed and analysed.
The primary objective of this post market clinical follow-up (PMCF) investigation is to confirm the safety and performance of Avance®Solo and Avance®Solo Adapt NPWT Systems in low to moderate exuding chronic wounds when used in accordance with the Instructions for Use, for up to 28 days.
This study is open to adults with diabetic kidney disease. The purpose of the study is to find out whether a medicine called BI 685509 improves kidney function. Three different doses of BI 685509 are tested in this study. Participants get either one of the three doses of BI 685509 or placebo. It is decided by chance who gets which BI 685509 dose and who gets placebo. Participants take BI 685509 or placebo as tablets 3 times a day. Placebo tablets look like BI 685509 tablets but do not contain any medicine. Participants continue taking their usual medicine for diabetes and kidney disease throughout the study. Participants are in the study for about 7 months. During this time, they visit the study site about 11 times. Where possible, about 6 of the 11 visits can be done at the participant's home instead of the study site. The trial staff may also contact the participants by phone or video call. Kidney function is assessed based on the analysis of urine samples, which participants collect at home. At the end of the trial the results are compared between the different doses of BI 685509 and placebo. During the study, the doctors also regularly check the general health of the participants.
Implant placement in the posterior maxilla is compromised due to atrophy of the alveolar process and maxillary sinus pneumatisation. Bone augmentation is frequently necessary before or in conjunction with implant placement. The most commonly used method to augment the posterior maxillary involves maxillary sinus floor augmentation (MSFA) with autogenous bone graft or bone substitute. Autogenous bone graft harvesting is associated with risk of donor site morbidity and unpredictable resorption of graft. Thus, bone substitutes alone or in combination with autogenous bone are used increasingly to simplify the surgical procedure. Symbios biphasic biomaterial is a resorbable inorganic bone forming material derived from red algae consisting of 20% hydroxylapatite and 80% β-tricalciumphosphate with osteoconductive properties. Histologic and radiographic examinations indicate that β-tricalciumphosphate is slowly resorbed and replaced with bone. MSFA with β-tricalciumphosphate alone or in combination with autogenous bone or other bone substitutes have demonstrated high implant survival and new bone. Symbios xenograft granules is a porcine bone mineral with osteoconductive properties. Histologic and radiographic examinations indicate that xenograft is a non-resorbable graft material. MSFA with xenograft alone or in combination with autogenous bone have shown high implant survival and new bone. The objective is to test the H0-hypothesis of no difference in implant outcome after MSFA with autogenous bone graft or in combination with Symbios biphasic biomaterial or Symbios xenograft. 60 consecutively healthy patients with a missing posterior maxillary tooth/teeth will be randomly allocated to: 1) MSFA with autogenous bone graft, 2) MSFA with mixture of 50% autogenous bone graft and 50% Symbios biphasic biomaterial 3) MSFA with mixture of 50% autogenous bone graft and 50% Symbios xenograft. Implants will be inserted simultaneously with MSFA. Clinical and/or radiographical evaluation using periapical radiographs and Cone Beam Computer Tomography will be performed preoperatively, immediate postoperatively, before abutment connection, after prosthetic rehabilitation, and after one year to assess the treatment outcome and volumetric changes of the augmented area. Outcome include survival of suprastructures and implants, volumetric stability of graft, peri-implant marginal bone level, oral health related quality of life, and complications.
The aim is to investigate if iron deficiency at the time of colorectal cancer diagnosis has an influence on fatigue, quality of life, cognition and physical ability.
The ideal blood pressure management strategy during endovascular therapy (EVT) for acute ischemic stroke has not been defined. The aim of this pilot randomized clinical trial is to determine whether randomization to a standard versus individual blood pressure management strategy during the EVT procedure is feasible.
A randomised, double-blinded and placebo-controlled intervention study. The study aim to evaluate the feasibility, safety and pilot-efficacy of faecal microbiota transplantation as a treatment of severe gastrointestinal neuropathy in patients with diabetes mellitus type 1.
This study aims to investigate the degree of Health Technologies Readiness amongst patients with suspected breast cancer using the READHY-tool.